Next Article in Journal
Correction: Field, M. et al. AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients
Previous Article in Journal
Mutagenesis of α-Conotoxins for Enhancing Activity and Selectivity for Nicotinic Acetylcholine Receptors
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Toxins
Volume 11
Issue 2
10.3390/toxins11020114
toxins-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Developmental Toxicity of Mycotoxin Fumonisin B1 in Animal Embryogenesis: An Overview

by
Chompunut Lumsangkul
1,
Hsin-I Chiang
1,
Neng-Wen Lo
2,
Yang-Kwang Fan
1,* and
Jyh-Cherng Ju
1,3,4,5,*
1
Department of Animal Science, National Chung Hsing University, Taichung 40227, Taiwan
2
Department of Animal Science and Biotechnology, Tunghai University, Taichung 40704, Taiwan
3
Graduate Institute of Biomedical Sciences, China Medical University, Taichung 40402, Taiwan
4
Translational Medicine Research Center, China Medical University Hospital, Taichung 40402, Taiwan
5
Department of Bioinformatics and Medical Engineering, Asia University, Taichung 41354, Taiwan
*
Authors to whom correspondence should be addressed.
Toxins 2019, 11(2), 114; https://doi.org/10.3390/toxins11020114
Received: 22 January 2019 / Revised: 2 February 2019 / Accepted: 11 February 2019 / Published: 13 February 2019
(This article belongs to the Section Mycotoxins)
Browse Figures
Versions Notes

Abstract

:
A teratogenic agent or teratogen can disturb the development of an embryo or a fetus. Fumonisin B1 (FB1), produced by Fusarium verticillioides and F. proliferatum, is among the most commonly seen mycotoxins and contaminants from stale maize and other farm products. It may cause physical or functional defects in embryos or fetuses, if the pregnant animal is exposed to mycotoxin FB1. Due to its high similarity in chemical structure with lipid sphinganine (Sa) and sphingosine (So), the primary component of sphingolipids, FB1 plays a role in competitively inhibiting Sa and So, which are key enzymes in de novo ceramide synthase in the sphingolipid biosynthetic pathway. Therefore, it causes growth retardation and developmental abnormalities to the embryos of hamsters, rats, mice, and chickens. Moreover, maternal FB1 toxicity can be passed onto the embryo or fetus, leading to mortality. FB1 also disrupts folate metabolism via the high-affinity folate transporter that can then result in folate insufficiency. The deficiencies are closely linked to incidences of neural tube defects (NTDs) in mice or humans. The purpose of this review is to understand the toxicity and mechanisms of mycotoxin FB1 on the development of embryos or fetuses.
Keywords:
Fumonisin B1; developmental toxicity; embryogenesis; NTD; teratogen
Key Contribution: This review summarizes the developmental toxicity effect and possible mechanisms of mycotoxin Fumonisin B1 in several animal species, along with future perspectives in some related studies.

1. General Features of Fumonisin B1

Mycotoxin Fumonisins (FBs) are fungal secondary metabolites produced by Fusarium verticillioides and F. proliferatum. They are water soluble and contain two propane-1, 2, 3-tricarboxylic acid side chains, esterified to an aminopolyol backbone. Eighteen different related types have been identified and isolated [1,2]. Fumonisin B1 (FB1) is clearly the most abundant analogue and the most prevalent mycotoxin contamination found in stale corn [3,4,5,6,7,8,9].
FB1 contamination occurs in maize kernels and biosynthesis of FB1 within the environment of the fungus-colonized kernel can be affected by the kernel composition. FB1 production is at least five times higher in de-germed maize kernels than in germ tissue [10]. FB1 biosynthesis varies with the developmental age of the tissue with the highest level of FB1 appearing in the later stages of kernel development [11].
More than 50% of FB1 contamination has been found in spoiled corn and corn-based products, in many parts of the world. A wild range of concentrations of FB1 from 6 to 155,000 μg/kg was detected in the investigated corn samples [12,13,14,15,16,17,18,19] that exceeded both the U.S. Food and Drug Administration guidelines and the EU maximum limits in de-germed dry-milled corn products (2000 μg/kg of total FB) [4,5,6,7,8]. In South America, all Brazilian corn meal samples were found to contain 1310 to 19,230 μg/kg of FBs [17]. Maize and maize-based foods, such as the cornflakes and corn snacks, have become an integral part of human life, being consumed on a daily basis. It has been shown that total maize production increased from 832.5 to 1099 million metric tons, globally, between 2011 and 2018 [20,21]. Similarly, total corn consumption around the world summarized by USDA increased from 991 to 1131 thousand metric tons, between 2015 and 2018 [22].
According to WHO (2001), the maximum tolerable daily intake of FBs, for humans, is 2 μg/kg-BW (body weight) [23]. The European Commission (2006 and 2007) also established a maximal FB level of 1000 μg/kg in maize and maize-based food for humans, 800 μg/kg in maize-based breakfast cereals and snacks, and 200 μg/kg in maize-based infant food [24,25]. Therefore, children and infants are the main risk groups for FB1 toxicity. In Brazil, Tanzania, Guatemala, South Africa, and Argentina [26,27], an assessment revealed that human consumption of FB1 is above the tolerable daily level. Prevalence of esophageal cancer in Africa and Asia is also the highest in areas with high concentrations of FB1 contamination reported (between 140,480 and 155,000 μg/kg) [18,19]. As corn is also one of the primary components of animal feeds, animals are also among those at a high risk of FB1 contamination.
It has been reported that FB1 induces many animal diseases, such as equine leukoencephalomalacia [28], porcine pulmonary edema syndrome [29], hepatic tumor in rats [30], acute and fatal nephrotoxicity and hepatotoxicity in lambs [31]. Various degrees of toxic responses have been observed in chickens, ducklings, and turkey poults (e.g., decreased body weight gain, increased mortality, reduced size of the bursa of Fabricius, thymus, and spleen, myocardial degeneration, myocardial hemorrhage, alterations in the hemostatic mechanism and necrosis of hepatocytes) [32,33,34,35,36,37]. Therefore, mycotoxins not only pose a significant risk to human and animal health, but also impact food security and reduce livestock production. Doubtless, FB1 has been one of the most hazardous mycotoxins with regard to animal health that is tightly associated with economic losses.

2. Toxicokinetic of FB1

Mycotoxin FB1 is difficult to absorb and can be rapidly excreted (urinary and biliary) in most species [38]. In rats, FB1 can be excreted with feces (80%) and urine (3%), 96 h after intragastric administration of radiolabeled [14C] FB1. However, low but consistent FB1 levels can still be detected in the liver, kidneys, and blood [39]. Although the liver and kidneys are two major target organs retaining most of the absorbed toxins, FB1 is also found in serum and other tissues in pigs, after oral administration [40,41].
Intestinal absorption of FB1 and its biliary excretion are involved in the potential interactions between FB1 and cholesterol [42]. Through interactions with cholesterol and bile salts, such as sodium taurocholate, dietary FB1 could be incorporated into mixed micelles. Transfer of FB1 to micelles facilitates its intestinal absorption [42]. A few studies have looked at the transfer of FB1 from intestine to uterus or eggs. Previous studies in mammalian species suggested that FB1 could cross the placenta when the pregnant mouse was exposed to FB1, during the early gestation period (embryonic day 7.5–8.5, E7.5–8.5) [43]. In the early gestation stage, the placenta is not yet well-formed, which potentially leaves the embryos vulnerable to teratogenic insults. However, when pregnant rats were exposed to FB1 at later gestation period (E15), embryo development was not affected by the toxins, suggesting that the fully developed placenta might provide a protective barrier against a mycotoxin attack [44]. Nevertheless, no evidence has shown such FB1-placenta or FB1-egg transportation in humans and in avian species.
The FB1 molecule includes a long chain aminopentol backbone (AP1) with two ester-linked tricarballylic acids (TCA), in which AP1 originates from the hydrolysis of the tricarballylic acid side chains, at carbons 14 and 15; it is then replaced by the hydroxyl groups [45]. Recent studies have demonstrated that swine cecal microbiota can metabolize FB1 to partially hydrolysed FB1 (PHFB1) and a small amount of AP1 [46]. In weaning piglets, the presence of PHB1 and AP1 is found in tissues with mostly unmetabolized FB1 [47].
Based on the intraperitoneal or intravenous dosing, the kinetics of FB1 elimination is consistent with the one or two-compartment model. Depending on animal species, the initial elimination of FB1 is rapid with a half-life of approximately 10 to 116 min, among different animals [48,49,50,51,52,53]. In weaning piglets, however, FB1, PHB1, and AP1 were detected in animal tissues, during a ten-day long elimination period [47].

3. Mechanisms through Which the FB1 Exerts Its Developmental Toxicity

Teratogens are known to interfere with embryonic or fetal development and cause congenital malformations (birth defects). Potential teratogens include radiation, maternal infections, chemicals and drugs, etc. [54]. In the case of corn contaminated with FB1, physical or functional defects in human and animal embryos or fetuses are possible when pregnant mothers are exposed. Therefore, FB1 has also been proven to be among those potential teratogens during embryonic development.
The best-known mechanism of action for FB1 is closely associated with sphingolipid metabolisms. Due to the similarity of its chemical structure (Figure 1) with Sphinganine (Sa) and sphingosine (So) [1,2,3,55], FB1 can interfere with the metabolism of Sa and So, the primary components of sphingolipids. Sphingolipids are widely distributed compounds and are often part of biomembranes. They regulate critical cell functions, such as cell proliferation, differentiation, and apoptosis [56,57]. Therefore, during exposure, FB1 serves as a competitive inhibitor for the Sa and So key enzymes in the de novo synthesis of ceramide, complicating the sphingolipid biosynthesis pathway (Figure 2) [58,59,60]. Inhibition of the ceramide synthase leads to a rapid increase of sphinganine, reduced sphingosine, elevated Sa/So, accumulations of the 1-phosphate metabolites of Sa/So, as well as the decreased downstream sphingolipids [61,62,63].
Disturbance in the sphingolipid metabolism is thought to be a major contributor to FB1 toxicity; it can also interfere with folate transporters. In other words, another developmental toxicity of FB1 is disruption of folate processing, due to its high-affinity for the folate transporter. This, in turn, can lead to an insufficient transfer of folates to a developing fetus, causing folate-deficient syndromes, during embryogenesis. This phenomenon is similar to that observed when pregnant animals are fed specific vitamin-deficient diets, such as folate-deficient diets. Therefore, FB1 inhibition of ceramide biosynthesis can be plausibly linked to folate insufficiency and is closely associated with an increased risk of neural tube defects (NTDs) [64,65,66,67,68,69].
A possible etiological factor for embryo deaths and fetal malformations is maternal toxicity [70,71,72]. Collins et al. suggested that FB1 was not teratogenic but that developmental variations induced by the mycotoxin were secondary to maternal toxicity. Overall, FB1 exerts secondary to maternal toxicity, which includes growth impairment at high doses and fetal death in utero. In this study, signs of maternal toxicity (increased Sa/So ratios characteristic in maternal livers, kidneys, serum, and brains) were observed in kidneys and livers in all FB1-treated groups, but with no effect in fetuses [73]. Similarly, Reddy et al. found FB1-treated mice had increased Sa/So ratios in maternal organs, but not in fetal livers [74]. Therefore, the effects of FB1 on fetuses, should be considered as secondary to maternal toxicity.

4. Fumonisin B1 and Developmental Toxicity in Animals

As mentioned previously, mycotoxin FB1 might act as an embryonic or fetal cytotoxic agent (secondary to maternal toxicity), which results in growth retardation and developmental abnormalities, and indirectly induces NTDs when administered to pregnant animals. Previous studies about FB1 on developmental toxicity in rats, Syrian hamsters, mice, rabbits, humans, ruminants, and chickens are reviewed and summarized in Table 1.

4.1. Mammalian Models

4.1.1. Rats

In vitro studies have shown that FB1 retarded the growth of cultured rat embryos exposed to FB1 concentrations ≥0.2 ppm, for 45 h, starting from E9.5. Phenotypic abnormalities significantly increased when FB1 concentrations were greater than 0.5 ppm and reached 100% prevalence at 1.01–40.4 ppm [44]. Similarly, in rat embryos cultured with aminopentol (AP1; 0, 2.17, 7.22, 21.7, 72.2, or 217 ppm), the hydrolysis product of FB1, a significant increase was observed in the incidence of abnormal embryos (NTDs and other abnormalities) [76]. In both studies, the observed abnormalities were mainly in conjunction with the retardation of overall growth and development, suggesting that both AP1 and FB1 uniformly exert embryo-toxicity, in detriment to the entire embryo.
In contrast, results from an in vivo study found no overt adverse effects on the reproductive performance of either male or female rats, or their offspring when the rats were fed with FB1 (1, 10, or 55 ppm), starting 9 and 2 weeks before mating. Briefly, litter weight gains in the 10 and 55 ppm FB1 groups were slightly decreased; however, gross litter weight and physical development of offspring were not affected. Furthermore, altered sphingolipid ratios, specifically increased sphinganine to sphingosine ratios, were found in the livers of dams from the highest (55 ppm) FB1 treatment group. However, sphingolipid ratios of abdominal sections, containing livers and kidneys, of fetuses showed no differences between the control and the highest dose litters [77].

4.1.2. Hamsters

In Syrian hamsters, fetal body weight and crown-rump length appeared to decrease with the increased fetal deaths observed in dams, when the hamsters were given an oral administration of 6, 12, or 18 mg/kg-BW of FB1 on E8 and E9, respectively [78]. A similar result was also reported in pregnant Syrian hamsters that were given 0, 8.7, 10.4, 12.5, 15, or 18 mg/kg-BW of FB1 by gavage, on E8 through E12. Their litter sizes were significantly reduced when fed with higher doses of FB1 at 15 or 18 mg/kg-BW [79].

4.1.3. Mice

Cultured mouse E9 embryos were exposed to a long-term (0, 0.72, 1.44, 2.16, 3.60, 5.05, 10.8, 18.0, 36.0, or 72.1 ppm FB1, for 26 h) or a short-term (36 ppm FB1 for 2 h) FB1 treatment. For 26 h of exposure, FB1 caused growth retardation and malformations of embryos, at all concentrations equal to or greater than 1.44 ppm. For instance, one of the NTD phenotypes (exencephaly) was observed at concentrations ≥1.44 ppm of FB1 treatments, and its incidence increased from 10% at 1.44 ppm to 48% at 72.1 ppm (the highest concentration). At a 2 h exposure with 36 ppm FB1, the mouse embryo showed a retarded growth, with NTDs and facial hypoplasia observed in 67% and 83% of the tested embryos, respectively, [80].
When inbred LM/Bc mice were given intraperitoneal dosages of FB1 (0, 5, 10, 15, or 20 mg/kg) on E7.5 and E8.5, the incidence of fetuses showing exencephaly increased from 5% at 5 mg/kg to 79% at 20 mg/kg-BW of FB1 treatments [43]. Similarly, Voss et al. found the incidence of NTD litters was 4/11 (36%), at 10 mg/kg-BW (maternal) of the mycotoxin given (intraperitoneal injection) to LM/Bc mice on E7 and E8 [64].
Other experiments have indicated that CD1 mice are more resistant to NTDs induced by FB1 than the LM/Bc mice. Tests on CD1 mice have shown that the fetal toxicity (fetal death and decreased fetal weight) was evident after exposure to FB1 [74]. Voss et al. reported that developmental NTDs were less than 10% when mice were given 10 mg/kg-BW of FB1 [81]; however, FB1 was found to be fetotoxic, at a maternal dose ≥45 mg/kg-BW, where 36% of mouse fetuses with NTDs were induced. Moreover, Liao et al. also showed that CD1 mice fed with 12.5 mg/kg had NTDs in 7.4% of the mouse fetuses examined [82].
The comparison between the LM/Bc and CD1 females by Voss et al. [83] revealed a 10% incidence (1/10 fetuses) of exencephaly in the LM/Bc mouse fetuses, when female mice were fed with diets contaminated with 150 ppm FB1; but no NTDs were found in the CD1 offspring, although the CD1 litters exhibited a higher fetal mortality. Conceivably, differential responses or sensitivity to FB1 treatment could also exist even between these two mouse strains and not only among different animal species.

4.1.4. Rabbits

When given to New Zealand White rabbits by gavage (0, 0.1, 0.5, or 1.0 mg/kg-BW on E3 through E19 embryos), FB1 caused maternal mortality and disrupted maternal sphingolipid metabolism at concentrations ≥0.5 mg/kg-BW. Apparently, FB1 is fetotoxic at the two highest doses of 0.5 and 1.0 mg/kg-BW, as indicated by the reduced fetal body, kidney, and liver weights [84]. Exposure of male rabbits to FB1 contaminated diets with up to 7.5 mg/kg FB1, depressed the testicular and epididymal sperm reserves, the sperm production, and potentially impaired reproduction of the buck, and in turn, induced embryo mortality, during later development [85]. Evidence of disrupted sphingolipid metabolism was not found in rabbit fetuses, suggesting that the effect of FB1 on rabbits were also secondary to maternal toxicity.

4.1.5. Humans

Although FB1 has been identified with significant health threats in livestock and many other animals, evidence for the same in humans is currently inconclusive. Some studies expressed concerns that exposure to FB1 might contribute to serious adverse health outcomes, such as cancers and birth defects. One study on the incidence of NTDs among Mexican Americans at the Texas–Mexico border, suggested that FB1 exposure in pregnant women might be a contributing factor to NTDs in babies. The NTD risk can increase in women consuming homemade tortillas, which contain approximately 0.234 ppm FB1, with daily exposure, approximately 0.1726 mg/day/kg-BW compared to the control group [91]. Callihan et al. suggested that the mechanism of FB1 action has been confirmed in humans [86]. The alteration of sphingosine 1-phosphate (S1P) and its receptors, during the development of the nervous system, were observed. For instance, human neuroepithelial cells (hES-NEP) treated with various concentrations of (0.00072, 0.0072, 0.072, 0.72, 7.2, or 72 ppm) FB1, for 48 h, caused the inhibition of ceramide synthases and resulted in an accumulation of sphingoid-based dihydrosphingosine and the bioactive lysophosphosphingolipid dihydro-sphingosine 1-phosphate (dhS1P).

4.1.6. Cattle

The study of FB1 on developmental toxicity in ruminants is relatively limited, compared to those in other animal species and humans. However, in vitro oocyte maturation (IVM) was compromised by FB1 treatments, when bovine cumulus-oocyte complexes (COCs) were matured for 22 h, in a maturation medium containing 3.6, 7.2, 14.4, 21.6, or 36.0 ppm of FB1. Oocytes matured in the medium with 7.2 ppm FB1, decreased the proportion of the two- to four-celled embryos; oocytes matured with 14.4 ppm FB1 had no changes in their cleavage rates but showed a reduced blastocyst rate on day 8, post-fertilization. When the highest concentration (36.0 ppm) of FB1 was used, the most prominent effect on oocyte development was observed, in which the oocytes could not be normally fertilized or developed to the blastocyst stage [87]. In general, bovine oocytes matured in FB1-containing medium, also compromised the quality of developing embryos.

4.2. Avian Species

Javed et al. inoculated chicken eggs with (0, 0.72, 7.2, or 72 ppm) FB1 or Fusarium proliferatum culture material extract (CME), to provide 14.4 ppm of FB1 and 2.82 ppm FB2, on day 1 or day 10 of the 21-day incubation period. They found FB1 increased embryo mortality from 50% to 100%, when inoculated with FB1, compared to a 100% mortality in the CME treatment. Early fetal abnormalities including hydrocephalus, enlarged beaks and elongated necks, were also observed in FB1-exposed embryos; pathologic changes were evident in livers, kidneys, heart, lungs, musculoskeletal system, intestines, testes, and brains, in these toxin-exposed embryos [88]. In agreement with Bacon et al., a significantly increased mortality of embryos was observed in the FB1-administered group [89]. Another study was performed by Henry et al. to confirm FB1 toxicity, where broiler embryos were injected with 0 to 0.25 ppm FB1, followed by 72 h of incubation. By day 18, after FB1 injection, the cumulative embryonic mortality (56%) drastically increased, compared to the control group (4%) [90]. It is, hence, clearly demonstrated that exposure to mycotoxin FB1 adversely affected embryo survival and development in poultry. Unlike mammalian species, however, it remains unclear whether maternal exposure to mycotoxin FB1 (acute and chronic) can cause accumulative effects that could directly carry over to the developing chick embryos. It would be of great interest to develop more in-depth studies to reveal this maternal–fetal portal of Fumonisin toxicity.

5. Concluding Remark

Mycotoxin FB1 apparently acts directly or indirectly as an embryotoxic or fetotoxic teratogen to cause growth retardation, delayed or incomplete organogenesis, malformations, and ultimately fetal death, in several species, largely in a dose-dependent manner. Based on histopathological and sphingolipid profile assessments of the dams, fetotoxicity secondary to maternal toxic effects are also prominent. The mechanism of action for the toxicity of mycotoxin FB1 is understood to be through the competitive inhibitors of ceramide synthase in the de novo sphingolipid biosynthetic pathway. However, there is still no adequate evidence to implicate the initial alterations caused by FB1, particularly during early embryogenesis; similar studies in domestic species are also largely unavailable. Nevertheless, comparative studies between sensitive and non-sensitive animals might be necessary to determine which animal model is most relevant to humans. It would be useful to further investigate the specific toxicity and derive more conclusive mechanisms in Homo sapiens. Furthermore, due to the frequent higher level of FB1 contaminants, compared to the safety allowance recommended by the European Union (Commission of European Communities) and the USFDA Center for Food Safety and Nutrition, it is essential to develop an effective strategy to minimize risks of FB1 exposure for both animal species and human beings.

Author Contributions

C.L., wrote the original draft, and prepared and edited the manuscript, J.C.J., N.W.L., H.I.C., and Y.K.F.; reviewed and revised the manuscript.

Funding

This research received no external funding.

Acknowledgments

We wish to thank Daniel Clinciu at the Biomedical Sciences, China Medical University (CMU), for his help in proofreading and editing this article. Work on this article was partially supported by the grants from Ministry of Science and Technology (106-2313-B-039-003-MY2), Taiwan, and the CMU Hospital (DMR-106-123; DMR-108-128).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Branham, B.E.; Plattner, R.D. Isolation and characterization of a new Fumonisin from liquid cultures of Fusarium moniliforme. J. Nat. Prod. 1993, 56, 1630–1633. [Google Scholar] [CrossRef]
  2. Cawood, M.E.; Gelderblom, W.C.A.; Vleggaar, R.; Behrend, Y.; Thiel, P.G.; Marasas, W.F.O. Isolation of the Fumonisin mycotoxins—A quantitative approach. J. Agric. Food Chem. 1991, 39, 1958–1962. [Google Scholar] [CrossRef]
  3. Voss, K.A.; Smith, G.W.; Haschek, W.M. Fumonisins: Toxicokinetics, mechanism of action and toxicity. Anim. Feed Sci. Technol. 2007, 137, 299–325. [Google Scholar] [CrossRef]
  4. Voss, K.A.; Riley, R.T. Fumonisin toxicity and mechanism of action: Overview and current perspectives. Food Saf. 2013, 1, 49–69. [Google Scholar] [CrossRef]
  5. Smith, G.W. Fumonisins. In Veterinary Toxicology, 3rd ed.; Gupta, R., Ed.; Elsevier: New York, NY, USA, 2018; pp. 1003–1018. [Google Scholar]
  6. Murphy, P.A.; Rice, L.G.; Ross, P.F. Fumonisin Bl, B2 and B3 content of Iowa, Wisconsin and Illinois cornand corn screenings. J. Agric. Food Chem. 1993, 41, 263–266. [Google Scholar] [CrossRef]
  7. Thiel, P.G.; Marasas, W.F.O.; Sydenham, E.W.; Shephard, G.S.; Gelderblom, W.C.A.; Nieuwenhuis, J.J. Survey of Fumonisin production by Fusarium species. Appl. Environ. Microbiol. 1991, 57, 1089–1093. [Google Scholar] [PubMed]
  8. Chandrasekhar, S.; Sreelakshmi, L. Formal synthesis of Fumonisin B1, a potent sphingolipid biosynthesis inhibitor. Tetrahedron Lett. 2012, 53, 3233–3236. [Google Scholar] [CrossRef]
  9. ApSimon, J.W. Structure, synthesis, and biosynthesis of Fumonisin B1 and related compounds. Environ. Health Perspect. 2001, 109, 245–249. [Google Scholar] [CrossRef]
  10. Shim, W.B.; Flaherty, J.E.; Woloshuk, C.P. Comparison of Fumonisin B1 biosynthesis in maize germ and degermed kernels by Fusarium verticillioides. J. Food Prot. 2003, 66, 2116–2122. [Google Scholar] [CrossRef]
  11. Warfield, C.Y.; Gilchrist, D.G. Influence of kernel age on Fumonisin B1 production in maize by Fusarium moniliforme. Appl. Environ. Microbiol. 1999, 65, 2853–2856. [Google Scholar]
  12. Liu, Y.X.; Jiang, Y.; Li, R.J.; Pang, M.H.; Liu, Y.C.; Dong, J.G. Natural occurrence of Fumonisins B1 and B2 in maize from eight provinces of China in 2014. Food Addit. Contam. B 2017, 10, 113–117. [Google Scholar] [CrossRef] [PubMed]
  13. Pinotti, L.; Ottoboni, M.; Giromini, C.; Dell’Orto, V.; Cheli, F. Mycotoxin Contamination in the EU Feed Supply Chain: A Focus on Cereal Byproducts. Toxins 2016, 8, 45. [Google Scholar] [CrossRef] [PubMed]
  14. Tseng, C.T.; Liu, T.Y. Occurrence of Fumonisin B1 in maize imported into Taiwan. Int. J. Food Microbiol. 2001, 65, 23–26. [Google Scholar] [CrossRef]
  15. Tseng, C.T.; Liu, T.Y. Occurrence of Fumonisin B1 and B2 in corn-based foodstuffs in Taiwan market. Mycopathologia 1997, 137, 57–61. [Google Scholar] [CrossRef] [PubMed]
  16. Tseng, C.T.; Liu, T.Y. Natural Occurrence of Fumonisins B1 and B2 in Domestic Maize of Taiwan. Agric. Food Chem. 1999, 47, 4799–4801. [Google Scholar] [CrossRef]
  17. Bittencourt, A.B.F.; Oliveira, C.A.F.; Dilkin, P.; Correa, B. Mycotoxin occurrence in corn meal and flour traded in Sao Paulo, Brazil. Food Control 2005, 16, 117–120. [Google Scholar] [CrossRef]
  18. Chu, F.S.; Li, G.Y. Simultaneous occurrence of Fumonisin B1 and other mycotoxins in moldy corn collected from the People’s Republic of China in regions with high incidences of esophageal cancer. Appl. Environ. Microbiol. 1994, 60, 847–852. [Google Scholar] [PubMed]
  19. Rheeder, J.; Marasas, W.; Theil, P.; Sydenham, E.; Shephard, G.; Van Schalkwyk, D. Fusarium moniliforme and Fumonisins in corn in relation to human esophageal cancer in Transkei. Phytopathology 1992, 82, 353–357. [Google Scholar] [CrossRef]
  20. World Agricultural Production Foreign Agricultural Service Circular WAP 3–13 March 2013. Available online: http://www.fas.usda.gov/data/world-agricultural-production (accessed on 13 March 2013).
  21. World Agricultural Production Foreign Agricultural Service Circular WAP 12–18 December 2018. Available online: http://www.fas.usda.gov/data/world-agricultural-production (accessed on 18 December 2018).
  22. World Agricultural Production Foreign Agricultural Service Circular. Grain: World Markets and Trade December 2018. Available online: http://www.fas.usda.gov/data/grain-world-markets-and-trade (accessed on 18 December 2018).
  23. World Health Organization (WHO). Fumonisins . In Safety Evaluation of Certain Mycotoxins in Food; WHO Food Additives Series 47; FAO Food and Nutrition Paper 74; WHO: Geneva, Switzerland, 2001. [Google Scholar]
  24. European Commission (EC). Regulation (EC) No. 1881/2006 of 19/12/2006. Off. J. Eur. Union 2006, L364, 5–24. [Google Scholar]
  25. European Commission (EC). Regulation (EC) No. 1126/2007 of 28/9/2007. Off. J. Eur. Union 2007, L255, 14–17. [Google Scholar]
  26. Martin, S.; Ramos, A.J.; Cano-Sancho, G.; Sanchis, V. Mycotoxins: Occurrence, toxicology, and exposure assessment. Food Chem. Toxicol. 2013, 60, 218–237. [Google Scholar] [CrossRef] [PubMed]
  27. Scientific Committee on Food (SCF). Updated Opinion of the Scientific Committee on Food on Fumonisin B1, B2 and B3; Scientific Committee on Food SCF/CS/CNTM/MYC/28 Final; Directorate—Scientific Opinions; European Commission: Brussels, Belgium, 2003. [Google Scholar]
  28. Marasas, W.F.O.; Kellerman, T.S.; Pienaar, J.G.; Naude, T.W. Leukoencephalomalacia: A mycotoxicosis of Equidae caused by Fusarium moniliforme Sheldon. Onderstepoort J. Vet. Res. 1976, 43, 113–122. [Google Scholar] [PubMed]
  29. Kriek, N.P.J.; Kellerman, T.S.; Marasas, W.F.O. A comparative study of the toxicity of Fusarium verticilliodes (F. moniliforme) to horses, primates, pigs, sheep and rats. Onderstepoort J. Vet. Res. 1981, 4, 129–131. [Google Scholar]
  30. Gelderblom, W.C.A.; Snyman, S.D. Mutagenicity of potentially carcinogenic mycotoxins produced by Fusarium moniliforme. Mycotoxin Res. 1991, 7, 46–52. [Google Scholar] [CrossRef] [PubMed]
  31. Edrington, T.S.; Kamps-Holtzapple, C.A.; Harvey, R.B.; Kubena, L.F.; Elissalde, M.H.; Rottinghaus, G.E. Acute hepatic and renal toxicity in lambs dosed with Fumonisin-containing culture material. J. Anim. Sci. 1995, 73, 508–515. [Google Scholar] [CrossRef] [PubMed]
  32. Jeschke, N.; Nelson, P.E.; Marasas, W.F.O. Toxicity to ducklings of Fusarium moniliforme isolated from corn intended for use in poultry feed. Poult. Sci. 1987, 66, 1619–1623. [Google Scholar] [CrossRef]
  33. Engelhardt, J.A.; Carlton, W.W.; Tuite, J.F. Toxicity of Fusarium moniliforme var. subglutinans for chicks, ducklings and turkey poults. Avian Dis. 1989, 33, 357–360. [Google Scholar]
  34. Marijanovic, D.R.; Holt, P.; Norred, W.P.; Bacon, C.W.; Voss, K.A.; Stancel, P.C. Immunosuppressive effects of Fusarium moniliforme corn cultures in chicken. Poult. Sci. 1991, 70, 1895–1901. [Google Scholar] [CrossRef]
  35. Javed, T.; Bennett, G.A.; Richard, J.L.; Dombrink-Kurtzman, M.A.; Cote, L.M.; Buck, W.B. Mortality in broiler chicks on feed amended with Fusarium proliferatum culture material or with purified Fumonisin B1 and moniliforme. Mycopathologia 1993, 123, 171–184. [Google Scholar] [CrossRef]
  36. Espada, Y.; Gopegui, R.R.; Cuadradas, C.; Cabanes, F.J. Fumonisin mycotoxicoses in broilers: Plasma protein and coagulation modifications. Avian Dis. 1997, 41, 73–79. [Google Scholar] [CrossRef]
  37. Weibking, T.S.; Ledoux, D.R.; Brown, T.P.; Rottinghaus, G.E. Fumonisin toxicity in turkeys. J. Vet. Diagn. Investig. 1993, 5, 75–83. [Google Scholar] [CrossRef] [PubMed]
  38. Joint Expert Committee on Food Additives 47 (JECFA). Fumonisins, 47th Report of the Joint Expert Committee on Food Additives; World Health Organization: Geneva, Switzerland, 2001. [Google Scholar]
  39. Norred, W.P.; Plattner, R.D.; Chamberlain, W.J. Distribution and excretion of 14C Fumonisin B1 in male sprague-dawley rats. Nat. Toxins 1993, 1, 341–346. [Google Scholar] [CrossRef] [PubMed]
  40. Meyer, K.; Mohr, K.; Bauer, J.; Horn, P.; Kovács, M. Residue formation of Fumonisin B1 in porcine tissues. Food Addit. Contam. 2003, 20, 639–647. [Google Scholar] [CrossRef] [PubMed]
  41. Fodor, J.; Meyer, K.; Riedlberger, M.; Bauer, J.; Horn, P.; Kovacs, F.; Kovacs, M. Distribution and elimination of Fumonisin analogues in weaned piglets after oral administration of Fusarium verticillioides fungal culture. Food Addit. Contam. 2006, 23, 492–501. [Google Scholar] [CrossRef] [PubMed]
  42. Mahfoud, R.; Maresca, M.; Santelli, M.; Pfohl-Leszkowicz, A.; Puigserver, A.; Fantini, J. pH-dependent interaction of Fumonisin B1 with cholesterol: Physicochemical and molecular modeling studies at the air-water interface. J. Agric. Food Chem. 2002, 50, 327–331. [Google Scholar] [CrossRef] [PubMed]
  43. Gelineau-van Waes, J.; Starr, L.; Maddox, J.; Aleman, F.; Voss, K.A.; Wilberding, J.; Riley, R.T. Maternal Fumonisin exposure and risk for neural tube defects: Mechanisms in an in vivo mouse model. Birth Defects Res. A Clin. Mol. Teratol. 2005, 73, 487–497. [Google Scholar] [CrossRef] [PubMed]
  44. Flynn, T.J.; Pritchard, D.; Bradlaw, J.; Eppley, R.; Page, S. In vitro embryo toxicity of Fumonisin B1 evaluated with cultured post implantation staged embryos. Toxicol. In Vitro 1996, 9, 271–279. [Google Scholar]
  45. Merrill, A.H.; Wang, E.; Gilchrist, D.G.; Riley, R.T. Fumonisins and other inhibitors of de novo sphingolipid biosynthesis. Adv. Lipid Res. 1993, 26, 215–234. [Google Scholar]
  46. Fodor, J.; Meyer, K.; Gottschalk, C.; Mamet, R.; Kametler, L.; Bauer, J.; Horn, P.; Kovacs, F.; Kovacs, M. In vitro microbial metabolism of Fumonisin B1. Food Addit. Contam. 2007, 24, 416–420. [Google Scholar] [CrossRef]
  47. Fodor, J.; Balogh, K.; Weber, M.; Miklós, M.; Kametler, L.; Pósa, R.; Mamet, R.; Bauer, J.; Horn, P.; Kovács, F.; et al. Absorption, distribution and elimination of Fumonisin B(1) metabolites in weaned piglets. Food Addit. Contam. 2008, 25, 88–96. [Google Scholar] [CrossRef]
  48. Shephardm, G.S.; Thiel, P.G.; Sydenham, E.W.; Alberts, J.F.; Gelderblom, W.C. Fate of a single dose of the 14C-labelled mycotoxin, Fumonisin B1, in rats. Toxicon 1992, 30, 768–770. [Google Scholar] [CrossRef]
  49. Shephard, G.S.; Thiel, P.G.; Sydenham, E.W.; Savard, M.E. Fate of a single dose of 14C-labelled Fumonisin B1 in vervet monkeys. Nat. Toxins 1995, 3, 145–150. [Google Scholar] [CrossRef] [PubMed]
  50. Prelusky, D.B.; Savard, M.E.; Trenholm, H.L. Pilot study on the plasma pharmacokinetics of Fumonisin B1 in cows following a single dose by oral gavage or intravenous administration. Nat. Toxins 1995, 3, 389–394. [Google Scholar] [CrossRef] [PubMed]
  51. Vudathala, D.K.; Prelusky, D.B.; Ayroud, M.; Trenholm, H.L.; Miller, J.D. Pharmacokinetic fate and pathological effects of 14C Fumonisin B1 in laying hens. Nat. Toxins 1994, 2, 81–88. [Google Scholar] [CrossRef] [PubMed]
  52. Prelusky, D.B.; Miller, J.D.; Trenholm, H.L. Disposition of 14C-derived residues in tissues of pigs fed radiolabelled Fumonisin B1. Food Addit. Contam. 1996, 13, 155–162. [Google Scholar] [CrossRef] [PubMed]
  53. Tardieu, D.; Bailly, J.D.; Skiba, F.; Grosjean, F.; Guerre, P. Toxicokinetics of Fumonisin B1 in turkey poults and tissue persistence after exposure to a diet containing the maximum European tolerance for Fumonisins in avian feeds. Food. Chem. Toxicol. 2008, 46, 3213–3218. [Google Scholar] [CrossRef] [PubMed]
  54. Faqi, A.S.; Hoberman, A.; Lewis, E.; Stump, D. Developmental and Reproductive Toxicology. In A Comprehensive Guide to Toxicology in Preclinical Drug Development; Faqi, A.S., Ed.; Elsevier: New York, NY, USA, 2013; pp. 335–364. [Google Scholar]
  55. Braun, M.S.; Wink, M. Exposure, occurrence, and chemistry of Fumonisins and their cryptic derivatives. Compr. Rev. Food Sci. Food Saf. 2018, 2018, 769–791. [Google Scholar] [CrossRef]
  56. Rao, R.P.; Vaidyanathan, N.; Rengasamy, M.; Oommen, A.M.; Somaiya, N.; Jagannath, M.R. Sphingolipid Metabolic Pathway: An Overview of Major Roles Played in Human Diseases. J. Lipids 2013, 2013, 1–12. [Google Scholar]
  57. Chen, Y.; Liu, Y.; Sullards, M.C.; Merrill, A.H. An introduction to sphingolipid metabolism and analysis by new technologies. NeuroMol. Med. 2010, 12, 306–319. [Google Scholar] [CrossRef]
  58. Stockmann-Juvala, H.; Savolainen, K. A review of the toxic effects and mechanisms of action of Fumonisin B1. Hum. Exp. Toxicol. 2008, 27, 799–809. [Google Scholar] [CrossRef]
  59. Voss, K.A.; Riley, R.T.; Gelineau-Van Waes, J. Fumonisins. In Reproductive and Developmental Toxicology, 1st ed.; Gupta, R., Ed.; Elsevier: New York, NY, USA, 2011; pp. 725–737. [Google Scholar]
  60. Voss, K.A.; Riley, R.T.; Gardner, N.M.; Gelineau-Van Waes, J. Fumonisins. In Reproductive and Developmental Toxicology, 2nd ed.; Gupta, R., Ed.; Elsevier: New York, NY, USA, 2017; pp. 925–943. [Google Scholar]
  61. Wang, E.; Norred, W.P.; Bacon, C.W.; Riley, R.T.; Merril, A.H. Inhibition of Sphingolipid Biosynthesis by Fumonisins. J. Biol. Chem. 1991, 266, 14486–14490. [Google Scholar] [PubMed]
  62. Voss, K.A.; Riley, R.T.; Snook, M.E.; Gelineau-van Waes, J. Reproductive and sphingolipid metabolic effects of Fumonisin B1 and its alkaline hydrolysis product in LM/Bc mice: Hydrolyzed Fumonisin B1 did not cause neural tube defects. Toxicol. Sci. 2009, 112, 459–467. [Google Scholar] [CrossRef]
  63. Merrill, A.H., Jr.; Sullards, M.C.; Wang, E.; Voss, K.A.; Riley, R.T. Sphingolipid metabolism: Roles in signal transduction and disruption by Fumonisins. Environ. Health Perspect. 2001, 109, 283–289. [Google Scholar] [PubMed]
  64. Voss, K.A.; Riley, R.T.; Gelineau-van Waes, J. Fumonisin B1 induced neural tube defects were not increased in LM/Bc mice fed folate-deficient diet. Mol. Nutr. Food Res. 2014, 58, 1190–1198. [Google Scholar] [CrossRef] [PubMed]
  65. Marasas, W.F.O.; Riley, R.T.; Hendricks, K.A.; Stevens, V.L.; Sadler, T.W.; Gelineau-van Waes, J.; Missmer, S.T.; Cabrera, J.; Torres, O.; Gelderblom, W.C.; et al. Fumonisins disrupt sphingolipid metabolism, folate transport, and neural tube development in embryo culture and in vivo: A potential risk factor for human neural tube defects among populations consuming Fumonisin-contaminated maize. J. Nutr. 2004, 134, 711–716. [Google Scholar] [CrossRef]
  66. Gelineau-van Waes, J.; Voss, K.A.; Stevens, V.L.; Speer, M.C.; Riley, R.T. Maternal Fumonisin Exposure as a Risk Factor for Neural Tube Defects. Adv. Food Nutr. Res. 2009, 56, 145–181. [Google Scholar]
  67. Saitsu, H.; Ishibashi, M.; Nakano, H.; Shiota, K. Spatial and temporal expression of folate-binding protein 1 (Fbp1) is closely associated with anterior neural tube closure in mice. Dev. Dyn. 2003, 226, 112–117. [Google Scholar] [CrossRef]
  68. Stevens, V.L.; Tang, J. Fumonisin B1-induced sphingolipid depletion inhibits vitamin uptake via the glycosylphosphatidylinositol-anchored folate receptor. J. Biol. Chem. 1997, 272, 18020–18025. [Google Scholar] [CrossRef]
  69. Abdel Nour, A.M.; Ringot, D.; Gueant, J.L.; Chango, A. Folate receptor and human reduced folate carrier expression in HepG2 cell line exposed to Fumonisin B1 and folate deficiency. Carcinogenesis 2007, 28, 2291–2297. [Google Scholar] [CrossRef]
  70. Khera, K.S. Maternal toxicity: A possible etiological factor in embryo-fetal deaths and fetal malformations of rodent-rabbit species. Teratology 1985, 31, 129–153. [Google Scholar] [CrossRef]
  71. Giavini, E.; Menegola, E. The problem of maternal toxicity in developmental toxicity studies. Regul. Toxicol. Pharmacol. 2012, 62, 568–570. [Google Scholar] [CrossRef] [PubMed]
  72. Danielsson, B.R. Maternal toxicity. Methods. Mol. Biol. 2013, 947, 311–325. [Google Scholar]
  73. Collins, T.F.; Sprando, R.L.; Black, T.N. Effects of Fumonisin B1 in pregnant rats: Part 2. Food Chem. Toxicol. 1998, 36, 673–685. [Google Scholar] [CrossRef]
  74. Reddy, R.V.; Johnson, G.; Rottinghaus, G.E.; Casteel, S.W.; Reddy, C.S. Developmental effects of Fumonisin B1 in mice. Mycopathologia 1996, 134, 161–166. [Google Scholar] [CrossRef] [PubMed]
  75. Dragan, Y.P.; Bidlack, W.R.; Cohen, S.M.; Goldsworthy, T.L.; Hard, G.C.; Howard, P.C.; Riley, R.T.; Voss, K.A. Implications of Apoptosis for Toxicity, Carcinogenicity, and Risk Assessment: Fumonisin B1 as an Example. Toxicol. Sci. 2001, 61, 6–17. [Google Scholar] [CrossRef]
  76. Flynn, T.J.; Stack, M.E.; Troy, A.L.; Chirtel, S.J. Assessment of the embryotoxic potential of the total hydrolysis product of Fumonisin B1 using cultured organogenesis-staged rat embryos. Food Chem. Toxicol. 1997, 35, 1135–1141. [Google Scholar] [CrossRef]
  77. Voss, K.A.; Bacon, C.W.; Norred, W.P.; Chapin, R.E.; Chamberlain, W.J.; Plattner, R.D. Meredith FI. Studies on the reproductive effects of Fusarium moniliforme culture material in rats and the biodistribution of [14C] Fumonisin B1 in pregnant rats. Nat. Toxins 1996, 4, 24–33. [Google Scholar] [CrossRef]
  78. Floss, J.L.; Casteel, S.W.; Johnson, G.C.; Rottinghaus, G.E.; Krause, G.F. Developmental toxicity of Fumonisin in Syrian hamsters. Mycopathologia 1994, 128, 33–38. [Google Scholar] [CrossRef]
  79. Penner, J.D.; Casteel, S.W.; Pittman, L.; Rottinghaus, G.E.; Wyatt, R.D. Developmental toxicity of purified Fumonisin B1 in pregnant Syrian hamsters. J. Appl. Toxicol. 1998, 18, 197–203. [Google Scholar] [CrossRef]
  80. Sadler, T.W.; Merrill, A.H.; Stevens, V.L.; Sullards, M.C.; Wang, E.; Wang, P. Prevention of Fumonisin B1–induced neural tube defects by folic acid. Teratology 2002, 66, 169–176. [Google Scholar] [CrossRef]
  81. Voss, K.A.; Riley, R.T.; Gelineau-Van Waes, J.B. Fetotoxicity and neural tube defects in CD1 mice exposed to the mycotoxin Fumonisin B1. Mycotoxins 2007, 57, 67–72. [Google Scholar] [CrossRef]
  82. Liao, Y.J.; Yang, J.R.; Chen, S.E.; Wu, S.J.; Huang, S.Y.; Lin, J.J.; Chen, L.R.; Tang, P.C. Inhibition of Fumonisin B1 Cytotoxicity by Nanosilicate Platelets during Mouse Embryo Development. PLoS ONE 2014, 9, e112290. [Google Scholar] [CrossRef] [PubMed]
  83. Voss, K.A.; Gelineau-van Waes, J.B.; Riley, R.T. Fumonisins: Current research trends in developmental toxicology. Mycotoxin Res. 2006, 22, 61–69. [Google Scholar] [CrossRef] [PubMed]
  84. LaBorde, J.B.; Terry, K.K.; Howard, P.C.; Chen, J.J.; Collins, T.F.X.; Shackelford, M.E.; Hansen, D.K. Lack of embryotoxicity of Fumonisin B1 in New Zealand white rabbits. Fundam. Appl. Toxicol. 1997, 40, 120–128. [Google Scholar] [CrossRef]
  85. Ewuola, E.O.; Egbunike, G.N. Effects of dietary Fumonisin B1 on the onset of puberty, semen quality, fertility rates and testicular morphology in male rabbits. Reproduction 2010, 139, 439–445. [Google Scholar] [CrossRef]
  86. Callihan, P.; Zitomer, N.C.; Stoeling, M.V.; Kennedy, P.C.; Lynch, K.R.; Riley, R.T.; Hooks, S.B. Distinct generation, pharmacology, and distribution of sphingosine 1-phosphate and dihydrosphingosine 1-phosphate in human neural progenitor cells. Neuropharmacology 2012, 62, 988–996. [Google Scholar] [CrossRef]
  87. Kalo, D.; Roth, Z. Involvement of the sphingolipid ceramide in heat shock induced apoptosis of bovine oocytes. Reprod. Fertil. Dev. 2011, 23, 876–888. [Google Scholar] [CrossRef]
  88. Javed, T.; Richard, J.L.; Bennett, G.A.; Dombrink-Kurtzman, M.A.; Bunte, R.M.; Koelkebeck, K.W.; Cote, L.M.; Leeper, R.W.; Buck, W.B. Embryopathic and embryocidal effects of purified Fumonisin B1 or Fusarium proliferatum culture material extract on chicken embryos. Mycopathologia 1993, 123, 185–193. [Google Scholar] [CrossRef]
  89. Bacon, C.W.; Porter, J.K.; Norred, W.P. Toxic interaction of Fumonisin B1 and fusaric acid measured by injection into fertile chicken egg. Mycopathologia 1995, 129, 29–35. [Google Scholar] [CrossRef]
  90. Henry, M.H.; Wyatt, R.D. The Toxicity of Fumonisin B1, B2, and B3, individually and in combination, in chicken embryos. Poult. Sci. 2001, 80, 401–407. [Google Scholar] [CrossRef]
  91. Missmer, S.A.; Suarez, L.; Felkner, M.; Wang, E.; Merrill, A.H.; Rothman, K.J.; Hendricks, K.A. Exposure to Fumonisins and the occurrence of neural tube defects along the Texas-Mexico border. Environ. Health Perspect. 2006, 114, 237–241. [Google Scholar] [CrossRef] [PubMed]
Toxins 11 00114 g001 550
Figure 1. Comparison of chemical structure of FB1 and primary components of sphingolipids, sphinganine (Sa) and sphingosine (So). The chemical structure of FB1 has a high similarity to Sa and So, which all possess an amine group (red circle) attached to the long fatty-acid chain. FB1 also differs from Sa or So, by the absence of a hydroxymethyl group (blue circle) attached to the head group [1,2,3,55].
Figure 1. Comparison of chemical structure of FB1 and primary components of sphingolipids, sphinganine (Sa) and sphingosine (So). The chemical structure of FB1 has a high similarity to Sa and So, which all possess an amine group (red circle) attached to the long fatty-acid chain. FB1 also differs from Sa or So, by the absence of a hydroxymethyl group (blue circle) attached to the head group [1,2,3,55].
Toxins 11 00114 g001
Toxins 11 00114 g002 550
Figure 2. Inhibition of the ceramide synthesis pathway by FB1. In normal physiology, the amino group of Sphinganine (Sa) and Sphingosine (So) can form an amide bond with fatty acid carboxyl to produce a ceramide. Mycotoxin FB1 can bind to the catalytic site of ceramide synthase, resulting in an inhibition of the reduction of Sa with fatty acyl CoA forming dihydroceramide. Furthermore, re-acylation of So, derived from breaking down sphingolipids to form ceramide, is also inhibited by FB1 (red line) [56,59,60,61,62,63,75].
Figure 2. Inhibition of the ceramide synthesis pathway by FB1. In normal physiology, the amino group of Sphinganine (Sa) and Sphingosine (So) can form an amide bond with fatty acid carboxyl to produce a ceramide. Mycotoxin FB1 can bind to the catalytic site of ceramide synthase, resulting in an inhibition of the reduction of Sa with fatty acyl CoA forming dihydroceramide. Furthermore, re-acylation of So, derived from breaking down sphingolipids to form ceramide, is also inhibited by FB1 (red line) [56,59,60,61,62,63,75].
Toxins 11 00114 g002
Table
Table 1. The developmental toxicity of mycotoxin Fumonisin B1 in animals and humans.
Table 1. The developmental toxicity of mycotoxin Fumonisin B1 in animals and humans.
SpeciesFB1 Treatment and DosesDevelopmental ToxicityReference
Rat (Sprague-Dawley)Rat embryos cultured in 0.2 to 40.4 ppm FB1 for 45 h at embryonic day (E) 9.5Retarded development; increased abnormal embryos phenotype[44]
Rat (Sprague-Dawley)Rat embryos cultured in 0, 2.17, 7.22, 21.7, 72.2 or 217 ppm hydrolized FB1 (HFB1) for 45 h at E9.5Increased percentage of NTDs and other abnormalities[76]
Rat (Sprague-Dawley)Male and female rats fed 0, 1, 10, or 55 ppm FB1 9 or 2 wk prior to matingNo effect on the peformance of dam or embryos; maternal toxicity by altering sphingolipid metabolism in the livers of dam at the highest dose [77]
Syrian HamsterFemale hamsters fed 0, 6, 12, 18 mg/kg-BW by gavage on E8–E9Increased fetal death; malformation at the highest dose [78]
Syrian HamsterPregnant Syrian hamsters given 0, 8.7, 10.4, 12.5, 15, or 18 mg/kg-BW by gavage on E8–E12.Reduced litter size; decreased fetal weight; reduced body length [79]
Mouse (ICR)Mouse embryos cultured with 0, 0.72, 1.44, 2.16, 3.60, 5.05, 10.8, 18.0, 36.0 or 72.1 ppm for 26 h and 36 ppm for 2 hInduced facial NTDs; growth retardation [80]
Mouse (LM/Bc)Pregnant mice injected with 0, 5, 10, 15 and 20 mg/kg-BW/day via intraperitoneal on E7.5 and E8.5Increased exencephaly from 5% to 79% [44]
Mouse (LM/Bc)Female mice treated with 0, 2.5 or 10 mg/kg by intraperitoneal on E7 and E8NTDs (36%) in 10 mg/kg treated group [64]
Mouse (CD1)Female mice fed 0, 12.5, 25, 50 and 100 mg FB1/kg-BW by gavage from E7–E15Fetal toxicity; increased fetal death; decreased fetal weight [74]
Mouse (CD1)Pregnant mice injected with 15, 30 or 45 mg FB1/kg-BW/day (1st trial); 10, 23, 45 or 100 mg/kg-BW/day (2nd trial) via intraperitoneal at E7 and E8Fetotoxicity; increased NTDs (8–55%) [81]
Mouse (CD1)Pregnant mice fed 12.5 mg/kg FB1 at E7.5 and E8.5NTDs (7.4% exencephaly) [82]
Mouse (LM/Bc, CD1)Female mice fed 0, 50 or 150 mg/kg diet at wk 5 before mating and after mating until E1610% of exencephaly in LM/Bc mice (at 150 mg/kg); No NTDs but fetal death in CD1 mice [83]
Rabbits (New Zealand White)Rabbits fed 0, 0.1, 0.5, and 1.0 mg/kg-BW by gavage during E3–E19Decreased body and organ weights of fetuses [84]
Rabbits (NewZealand White x Chinchilla)Male rabbits fed 0.13, 5.0, 7.5 and 10 mg/kg for 28 wk then mated with female rabbitsInduced embryo mortality [85]
Human neural epithelial cellsCells treated with 0.00072, 0.0072, 0.072, 0.72, 7.2, and 72 ppm FB1 for 48 hAltered balance of Sphingosine 1-phosphate[86]
Bovine oocytesCumulus-oocyte complexes matured in 3.6, 7.2, 14.4, 21.6, or 36.0 ppm FB1-containing medium for 22 hDecreased percentages and quality of matured oocytes and embryos [87]
Chicken (Columbia x New Hampshire)Eggs inoculated with 0.72, 7.2 or 72 ppm of FB1 or 14.4 ppm FB1 + 2.82 ppm FB2, and 0.84 ppm moniliformin at the air sac on day 1 or day 10 of incubationIncreased mortality rates; altered brain, beak, and neck development; pathologic changes in livers, kidneys, heart, lungs, musculoskeletal system, intestines, testes, and brains[88]
Chicken embryos (White Leghorn)Chicken embryos injected with 0, 0.017, 0.085, 0.17, 0.425, 0.85, 1.275 and 1.74 ppm FB1 at day 1 of incubationIncreased embryonic death[89]
Chicken embryos (Peterson-Arbor Acres)Chicken embryos injected with 0 or 0.25 ppm FB1 at 72 h of incubationIncreased embryonic mortality on d 18[90]

Share and Cite

MDPI and ACS Style

Lumsangkul, C.; Chiang, H.-I.; Lo, N.-W.; Fan, Y.-K.; Ju, J.-C. Developmental Toxicity of Mycotoxin Fumonisin B1 in Animal Embryogenesis: An Overview. Toxins 2019, 11, 114. https://doi.org/10.3390/toxins11020114

AMA Style

Lumsangkul C, Chiang H-I, Lo N-W, Fan Y-K, Ju J-C. Developmental Toxicity of Mycotoxin Fumonisin B1 in Animal Embryogenesis: An Overview. Toxins. 2019; 11(2):114. https://doi.org/10.3390/toxins11020114

Chicago/Turabian Style

Lumsangkul, Chompunut, Hsin-I Chiang, Neng-Wen Lo, Yang-Kwang Fan, and Jyh-Cherng Ju. 2019. "Developmental Toxicity of Mycotoxin Fumonisin B1 in Animal Embryogenesis: An Overview" Toxins 11, no. 2: 114. https://doi.org/10.3390/toxins11020114

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop